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Abstract
Background: Lower urinary tract transitional cell carcinoma (TCC) is an important but
rarely described disease of cats.
Objectives: To report the clinical characteristics, treatments, and outcomes in a
cohort of cats with lower urinary tract TCC and to test identified variables for prog-
nostic relevance.
Animals: One-hundred eighteen client-owned cats with lower urinary tract carcinoma.
Methods: Medical records were retrospectively reviewed to obtain information
regarding clinical characteristics, treatments, and outcomes. Recorded variables were
analyzed statistically.
Results:Median age of affected cats was 15 years (range, 5.0-20.8 years) and median
duration of clinical signs was 30 days (range, 0-730 days). The trigone was the most
common tumor location (32/118; 27.1%) as assessed by ultrasound examination, cys-
toscopy, or both. Treatment was carried out in 73 of 118 (61.9%) cats. Metastatic dis-
ease was documented in 25 of 118 (21.2%) cats. Median progression-free survival
Abbreviations: BUN, blood urea nitrogen; CI, confidence interval; COX, cyclooxygenase; FNA, fine-needle aspirate; HR, hazard ratio; IQR, interquartile range; NSAIDs, nonsteroidal anti-
inflammatory drugs; OR, odds ratio; TCC, transitional cell carcinoma.
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and survival time for all cats were 113 days (95% confidence interval [CI], 69-153)
and 155 days (95% CI, 110-222), respectively. Survival increased significantly
(P < .001) when comparing cats across the ordered treatment groups: no treatment,
treatment without partial cystectomy, and treatment with partial cystectomy. Partial
cystectomy (hazard ratio [HR], 0.31; 95% CI, 0.17-0.87) and treatment with nonste-
roidal anti-inflammatory drugs (HR, 0.55; 95% CI, 0.33-0.93) were significantly associ-
ated with longer survival times.
Conclusions and Clinical Importance: The results support treatment using partial
cystectomy and NSAIDs in cats with TCC.
K E YWORD S
bladder, cat, cystectomy, neoplasia, urethra
1 | INTRODUCTION
The urinary bladder is the most common site of urinary tract neoplasia in
dogs and the second most common site of urinary tract neoplasia in cats
(after renal lymphoma).1,2 Transitional cell carcinoma (TCC) is the most
prevalent lower urinary tract cancer in dogs, and considerable informa-
tion regarding TCC is available for dogs, including common anatomical
locations of the tumor, risk factors, treatment, and prognosis.3-9 Many
treatment modalities have been described for dogs with TCC.3,10-12
When surgery is performed as part of treatment, complete excision of
lower urinary tract TCC lesions frequently is not achieved in dogs
because of trigonal or urethral location of the tumor or both, “field
effect” in which the entire urothelium undergoes malignant transforma-
tion and metastatic disease.3 Systemic medical treatment is considered
to be a mainstay of treatment in dogs with TCC and typically involves
chemotherapy and cyclooxygenase (COX) inhibitors.3,10 Radiation ther-
apy (with multiple protocols described) has been utilized to treat TCC in
dogs, but results still are reported uncommonly.3,11,12 Prognosis for dogs
with TCC is strongly associated with the tumor-node-metastasis (TNM)
stage at the time of diagnosis.3
In contrast to TCC in dogs, the incidence of TCC in cats is very low
and few studies have been published.13 The largest retrospective study
on TCC in cats to date documented 20 cases.14 Four of the 20 cats had
evidence of metastasis at the time of diagnosis, and treatments pursued
included piroxicam administration, chemotherapy, and surgical exci-
sion.14 The median survival time for all cats was 261 days, and 25% of
cats were lost to follow-up.14 Because of an insufficient number of cats
that received any given treatment protocol, it was not possible to deter-
mine a survival advantage for any specific treatment or combinations of
treatments.14 In addition, risk factors and prognostic indicators could
not be identified because of the small sample size of the study.14
Our objectives were to report the clinical characteristics, treat-
ments, and outcomes in a cohort of cats with TCC of the lower uri-
nary tract and to test identified variables for prognostic relevance. We
hypothesized that cats undergoing partial cystectomy as part of the
treatment regimen would have an improved prognosis compared to
cats that did not undergo partial cystectomy.
2 | MATERIALS AND METHODS
2.1 | Case selection criteria
A retrospective study was performed. The medical record databases
of 11 referral veterinary clinics (9 academic teaching hospitals and
2 private practice hospitals) were searched to identify cats with lower
urinary tract carcinoma that were presented to clinicians of various
specialty disciplines. To be included, cats were required to have cyto-
logical or histopathological confirmation of carcinoma from a mass in
either the bladder or urethra.
2.2 | Medical records review
Variables obtained from the medical records included signalment, his-
tory of lower urinary tract disease, clinical signs and duration of clini-
cal signs, physical examination findings, clinical pathology and urine
culture results, diagnostic imaging results, treatments pursued (sur-
gery, nonsteroidal anti-inflammatory drugs (NSAIDs), chemotherapy,
radiation therapy, and urethral or ureteral stent placement), docu-
mented complications and adverse events, cytology and histopathol-
ogy results, progression (ie, growth of primary tumor or recurrence) of
disease, documentation of metastatic disease, and timing and cause of
death. Complications were considered major if they required intensive
care, revision surgery, or both; all other complications were consid-
ered minor.
2.3 | Statistical analysis
Descriptive statistics were calculated, using tests of skewness and
kurtosis to evaluate normal distribution for continuous variables. Mul-
tivariable logistic regression was used to model risk factors associated
with receiving no treatment. Univariable analyses were performed
first and variables with P < .2 were tested in the final model. Variables
were retained in the multivariable model if P < .05 or if incorporation
changed odds ratios (OR) by >15%. The Kaplan-Meier product limit
method was used to estimate median progression-free survival (time
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from initial presentation to the study institution until the first instance
of documented progression, regional or distant metastasis, or death)
and overall survival (time from initial presentation to the study institu-
tion until death). Cats that did not reach these endpoints or were lost
to follow-up were censored in the respective analyses. Log rank test
for trend across ordered groups was used to compare unadjusted sur-
vival across the following treatment groups: no treatment, treatment
that did not include partial cystectomy, and treatment that included
partial cystectomy. Multivariable COX regression was used to model
risk factors associated with overall survival time as measured from the
date of initial presentation to the contributing hospital. Similarly,
univariable analyses were performed first and variables with P < .2
were tested in the final model. Variables were retained in the multi-
variable model if P < .05 or if incorporation changed hazard ratios
(HR) by >15%. Statistical software (Stata version 14.2, College Station,
Texas) was used for all analyses, and P < .05 was considered statisti-
cally significant.
3 | RESULTS
3.1 | Cats
Between 1991 and 2018, 118 cats from 11 institutions met inclusion
criteria. The contributing veterinary clinics were as follows: University
of California-Davis, School of Veterinary Medicine; Colorado State Uni-
versity, College of Veterinary Medicine; University of Pennsylvania,
School of Veterinary Medicine; University of Tennessee, College of Vet-
erinary Medicine; Oregon State University, Carlson College of Veteri-
nary Medicine; University of Georgia, College of Veterinary Medicine;
North Carolina State University, College of Veterinary Medicine; VCA
Canada—Alta Vista Animal Hospital; University of Illinois, College of
Veterinary Medicine; University of Guelph, Ontario Veterinary College;
and, Blue Pearl, Seattle Veterinary Specialists. The median age of
included cats was 15.0 years (interquartile range [IQR], 13.0-17.0;
range, 5.0-20.8 years). Cat breeds included 74 of 118 (62.7%) domestic
shorthair, 18 of 118 (15.3%) domestic longhair, 10 of 118 (8.5%)
domestic medium hair, 5 of 118 (4.2%) Siamese or Siamese Cross, and
2 of 118 (1.7%) each of Abyssinian, Persian, and Himalayan; 5 of
118 (4.2%) cats were other breeds. Sex included 62 of 117 (53.0%)
spayed females, 54 of 117 (46.2%) castrated males, and 1 of 117 (0.9%)
intact female; sex data was not provided for 1 cat.
3.2 | Lower urinary tract disease history and clinical
signs
A history of urinary tract infection was present in 28 of 118 (23.7%)
cats, feline idiopathic cystitis in 17 of 118 (14.4%) cats, and urolithiasis
in 12 of 118 (10.2%) cats. The majority of cats (92/118; 78.0%) had pre-
viously been presented to a veterinarian for signs of urinary tract dis-
ease. At least 1 clinical sign was noted in 111 of 118 (94.1%) cats, and
the median duration of clinical signs was 30 days (IQR, 9-105; range,
0-730 days). For the remaining 7 of 118 (5.9%) cats, TCC was found
incidentally during diagnostic imaging for assessment of other disease
processes. Clinical signs included hematuria in 74 of 118 (62.7%),
pollakiuria in 59 of 118 (50.0%), stranguria in 57 of 118 (48.3%),
anorexia in 26 of 118 (22.0%), lethargy in 26 of 118 (22.0%), vomiting
in 23 of 118 (19.5%), and abdominal pain in 12 of 118 (10.2%) cats. Of
cats with these clinical signs, 27 of 111 (24.3%) had 1 sign, 31 of
111 (27.9%) had 2 signs, 36 of 111 (32.4%) had 3 signs, 11 of
111 (9.9%) had 4 signs, 2 of 111 (1.8%) had 5 signs, 2 of 111 (1.8%) had
6 signs, and 2 of 111 (1.8%) had 7 signs. Urethral obstruction at presen-
tation was noted in 12 of 118 (10.2%) cats.
3.3 | Physical examination
At initial evaluation, cats had a median weight of 4.0 kg (IQR, 3.3-5.2;
range, 2.1-11.8 kg) and median body condition score of 5 of 9 (IQR,
3-6; range, 1-9/9). On abdominal palpation, 25 of 118 (21.2%) cats
were painful, and 22 of 118 (18.6%) cats had a palpable mass or thick-
ening of the urinary bladder region.
3.4 | Diagnostic results
Clinicopathologic results (CBC and serum biochemistry panel) were
available for 102 cats at initial evaluation by the contributing clinic;
94 of 102 samples (92.2%) were obtained before IV fluid administration,
and 8 of 102 samples (7.8%) were obtained during or after IV fluid
administration. Decreased hematocrit, increased serum creatinine and
increased blood urea nitrogen (BUN) concentrations were noted in
31 of 102 (30.4%), 34 of 102 (33.3%), and 58 of 102 (56.9%) cats,
respectively. Median BUN concentration was 43 mg/dL (IQR, 32-58;
range, 14-262), and median serum creatinine concentration was
1.9 mg/dL (IQR, 1.5-2.6; range, 4.5-15.6). Urinalysis was available for
69 cats. Median urine specific gravity was 1.016 (IQR 1.012-1.025,
range 1.000-1.056). Urine culture was performed on 67 cats at initial
evaluation by the contributing clinic; culture was performed on samples
obtained from voided samples in 10 of 67 (14.9%), cystocentesis in
25 of 67 (37.3%), catheterization in 1 of 67 (1.5%) cats, and method of
collection was not reported in 31 of 67 (46.3%) cats. Urine culture was
positive for bacterial growth in 10 of 67 (14.9%) cats; organisms cul-
tured included E. coli alone (5/10; 50%), E. coli and Enterococcus (1/10;
10%), E. coli and Bacillus (1/10; 10%), Enterococcus alone (1/10; 10%),
Enterococcus and Staphylococcus (1/10; 10%), and Serratia marcescens
(1/10; 10%).
Abdominal ultrasound examination, thoracic radiographs, abdominal
radiographs, and cystoscopy were performed on 110 of 118 (93.2%),
70 of 118 (59.3%), 25 (21.2%), and 5 (4.2%) cats respectively; abdominal
computed tomography was not performed on any cat. Diagnostic
images were reviewed and interpreted by board-certified radiologists.
Ultrasonographic findings included a single bladder mass (95/110;
86.4%), bladder wall thickening with a mass (8/110; 7.3%), and multiple
bladder masses (7/110; 6.4%). Tumors were located in the trigone in
32 of 118 (27.1%), ventral bladder wall in 28 of 118 (23.7%), bladder
apex in 20 of 118 (17.0%), dorsal bladder wall in 16 of 118 (13.6%),
multifocal or diffuse throughout the urinary bladder in 10 of 118 (8.5%),
and lateral bladder wall in 3 of 118 (2.5%) cats; tumor location was not
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reported in 9 of 118 (7.6%) cats. Urethral involvement of the tumor was
documented by ultrasound examination or cystoscopy in 14 of
118 (11.9%) cats, 1 of 14 (7.1%) cats of which were obstructed. Ureteral
obstruction was diagnosed in 14 of 118 (11.9%) cats by ultrasound
examination, and 6 of 118 (5.1%) cats had evidence of both urethral
and ureteral involvement (with 1 cat diagnosed with both urethral and
ureteral obstruction). Of the 5 cats that underwent cystoscopy, cystos-
copy allowed for visualization and further characterization of the TCC
lesion in the lower urinary tract in 4 of 5 (80.0%) cats and resulted in
poor visualization without detection of clinically relevant abnormalities
in 1 cat.
Cytology results, acquired by fine-needle aspirate (FNA), urine
cytospin, or traumatic urethral catheterization and reviewed by board-
certified pathologists, were available for 78 of 118 (66.1%) cats and
were consistent with TCC in 33 of 78 (42.3%) samples, carcinoma in
26 of 78 (33.3%) samples, or other (including epithelial hyperplasia, pro-
liferation, or atypia [6/78; 7.7%], inflammation [2/78; 2.6%], probable
neoplasia [2/78; 2.6%], inflammation with epithelial hyperplasia or
atypia [2/78; 2.6%], normal transitional epithelial cells [1/78; 1.3%], sar-
coma [1/78; 1.3%], and lymphosarcoma vs. carcinoma [1/78; 1.3%]) in
15 of 78 (19.2%) samples, and were inconclusive in 4 of 78 (5.1%) sam-
ples. Histopathology, obtained by surgical biopsy, cystoscopic biopsy,
necropsy, or some combination of these, was available for 62 of
118 (52.5%) cats; definitive diagnosis was obtained by cytology without
histopathology in 56 of 118 (47.5%) cats. Tumors were described as
infiltrative in 43 of 62 (69.4%), high grade in 2 of 62 (3.2%), and low
grade in 1 of 62 (1.6%) histopathologic samples. Tumors were not
described as in situ or aneuploid in any reports. Prostaglandin E mea-
surements and cyclooxygenase (COX) expression were not reported for
any tumor. Diagnosis was obtained by ultrasound-guided FNA alone
in 33 of 118 (28.0%) cats, surgical biopsy alone in 30 of 118 (25.4%)
cats, necropsy alone in 17 of 118 (14.4%) cats, urine cytospin alone in
14 of 118 (11.9%) cats, and traumatic urethral catheterization alone in
6 of 118 (5.1%) cats. Several cats had multiple diagnostic tests per-
formed (agreement was not noted between cytology and biopsy in all
cases): ultrasound-guided FNA and urine cytospin in 5 of 118 (4.2%)
cats, ultrasound-guided FNA and surgical biopsy in 4 of 118 (3.4%) cats,
ultrasound-guided FNA and necropsy in 3 of 118 (2.5%) cats, cystoscopic
biopsy and surgical biopsy in 2 of 118 (1.7%) cats, cystoscopic biopsy
and traumatic urethral catheterization in 1 cat, urine cytospin and
surgical biopsy in 1 cat, urine cytospin and necropsy in 1 cat, and a
combination of urine cytospin, traumatic urethral catheterization,
cystoscopic biopsy, and surgical biopsy in 1 cat.
Based on imaging, cytology, and histopathology results, 15 of
118 (12.7%) cats were considered to have metastatic disease at initial
evaluation; 9 of 118 (7.6%) cats had metastasis to regional lymph nodes
alone, 3 of 118 cats (2.5%) had abdominal carcinomatosis, 1 cat had
metastasis to a regional lymph node and omental tissue near the bladder,
1 cat had presumed pulmonary metastasis based on thoracic radiographs,
and 1 cat had both regional lymph node and presumed pulmonary metas-
tasis based on thoracic radiographs. Cases of nonpulmonary metastasis
were confirmed by cytology or histopathology, whereas cases of pulmo-
nary metastasis were reported as suspected based on radiographic inter-
pretation by a board-certified radiologist.
3.5 | Treatment
Information regarding treatment (specifically cystectomy) is found in
Table 1. Of the 2 cats with trigonal tumors that underwent partial
cystectomy, ureteral reimplantation was performed on 1 cat and re-
section of a ureteral papilla was performed on the other cat. The median
estimated percentage of bladder wall excised during partial cystectomy
(reported in 15/28 [53.6%] cats) was 50% (range, 20%-65%). Radical
cystectomy was not performed on any cat. Surgical biopsy without partial
cystectomy was performed on 7 of 118 (5.9%) cats. Tumor location of
cats undergoing surgical biopsy included dorsal wall (2/7; 28.6%), trigone
with extension into the ureters (1/7; 14.3%), dorsal and ventral wall (1/7;
14.3%), and multifocal or diffuse (1/7; 14.3%); location was not reported
in 1 cat. Excision was reportedly complete (ie, tumor-free margins on his-
topathology) after 9 of 28 (32.1%) partial cystectomies, incomplete (ie,
tumor cells extending to margins on histopathology) after 12 of
28 (42.9%) partial cystectomies, and not reported after 7 of 28 (25.0%)
partial cystectomies. Four cats had documented margins of normal blad-
der tissue with a histopathologically complete excision, and a range of
1 to 3 mm of normal bladder wall was noted.
TABLE 1 Information regarding treatment
Treatment pursued? Treatment
No 45 (38)
Single
modality
Multiple
modality
No
cystectomy
Partial cystectomy
Yes 73 (62) 35 (48) 38 (52) 45 (62) 28 (38)
Bladder location where cystectomy performed
Ventral
wall
Apex Dorsal
wall
Lateral
wall
Trigone Not
reported
9 8 6 2 2 1
Numbers refer to number (percentage) of cats. Nearly 2/3 of cats received treatment and 38% of those that received treatment underwent partial
cystectomy. Although many locations of the bladder were excised, the ventral wall and apex were most common.
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Three major postoperative complications occurred (septic peritonitis
[2/28; 7.1%] and uroperitoneum [1/28; 3.6%]) and 3 minor complications
occurred (transient urinary incontinence [1/28; 3.6%], massive abdominal
wall bruising [1/28; 3.6%], and hematuria and stranguria[(1/28; 3.6%] in
cats undergoing partial cystectomy. Of the 2 cats with trigonal tumors
that underwent partial cystectomy, both experienced major postoperative
complications (septic peritonitis [1/2; 50%] and uroperitoneum [1/2;
50%]). One cat that underwent surgical biopsy without cystectomy had a
major complication; during surgery, a cystostomy tube was placed and
leakage of the cystostomy tube (requiring revision surgery) was encoun-
tered postoperatively.
Improvement in clinical signs was reported after surgery in 21 of
28 (75.0%) cats that underwent partial cystectomy, but it is unknown if
this improvement can be completely attributed to surgery because many
cats underwent multimodality therapy. No improvement in clinical signs
was reported after surgery in 2 of 28 (7.1%) cats that underwent partial
cystectomy. Data regarding improvement was not available for the
remaining 5 cats that underwent partial cystectomy. After partial
cystectomy, 12 of 28 (42.9%) cats received no additional treatment, 7 of
28 (25.0%) cats received NSAIDs only, 6 of 28 (21.4%) cats received
chemotherapy and NSAIDs, and 3 of 28 (10.7%) cats received
chemotherapy only.
Nonsteroidal anti-inflammatory drugs were administered to 49 of
118 (41.5%) cats; 15 of 49 (30.6%) cats were treated only with NSAIDs,
and 34 of 49 (69.4%) cats were treated with NSAIDs as part of a multi-
ple modality treatment plan. Administered NSAIDs included piroxicam
only in 30 of 49 (61.2%) cats, meloxicam only in 14 of 49 (28.6%) cats,
robenacoxib only in 3 of 49 (6.1%) cats, and both piroxicam and
meloxicam (sequential) in 2 of 49 (4.1%) cats. Adverse events were
reported in 13 of 49 (26.5%) cats prescribed NSAIDs and included
acute onset or progression of azotemia (6/13; 46.2%), nausea, vomiting,
or regurgitation (3/13; 23.1%), inappetence (2/13; 15.4%), diarrhea with
or without melena (2/13; 15.4%), lethargy (1/13; 7.7%), constipation
(1/13; 7.7%), and hematuria (1/13; 7.7%). However, documentation of
these clinical signs as directly associated with NSAID administration
was not possible in at least 7 of 13 (53.8%) cats because of other con-
current treatments or progressive disease.
Chemotherapy was administered to 33 of 118 (28.0%) cats; 6 of
33 (18.2%) cats were treated with only chemotherapy and 27 of
33 (81.8%) cats were treated with chemotherapy as part of
multimodality (ie, surgery, NSAID administration, radiation therapy, or
some combination of these) treatment plan. The most common che-
motherapy protocol was mitoxantrone alone (17/33; 51.5%). Other
protocols included carboplatin alone (4/33; 12.1%); mitoxantrone and
vinblastine (2/33; 6.1%); mitoxantrone and chlorambucil (2/33; 6.1%);
chlorambucil alone (2/33; 6.1%); vinblastine alone (1/33; 3.0%); doxo-
rubicin and carboplatin (1/33; 3.0%); mitoxantrone and carboplatin
(1/33; 3.0%); mitoxantrone and cyclophosphamide (1/33; 3.0%);
mitoxantrone, vinblastine, and gemcitabine (1/33; 3.0%); and,
mitoxantrone, carboplatin, and vinblastine (1/33; 3.0%). For each pro-
tocol with multiple chemotherapy agents utilized, administration of
the agents was sequential rather than concurrent. Mitoxantrone was
administered as a first-line chemotherapy agent in 24 of 33 (72.7%)
cats. Adverse events were reported in 23 of 33 (69.7%) cats given
chemotherapy; grading of neutropenia was based on definitions used
by the Veterinary Co-operative Oncology Group—Common Terminol-
ogy Criteria for Adverse Events. Adverse events included gastrointes-
tinal signs, lethargy, or both (21/23; 91.3%), myelosuppression (5/23
[21.7%]; grade II neutropenia in 1/5 [20.0%], grade III neutropenia in
3/5 [60.0%], grade IV neutropenia in 1/5 [20.0%]), and azotemia
(6/23 [26.1%] with at least 2/6 [33.3%] of these cases possibly attrib-
uted to another cause of renal injury because azotemia was present
before chemotherapy). Reported clinical response rate (ie, improve-
ment of clinical signs) was 25 of 33 (75.8%) in cats given chemother-
apy as part of their treatment protocol. However, all but 6 of
33 (18.2%) cats underwent other forms of treatment, and in those
cats, improvement in clinical signs cannot be attributed to chemother-
apy alone. In the 6 cats that received chemotherapy alone, clinical
signs improved in 2 of 6 (33.3%) cats, but information regarding the
response in the other 4 of 6 (66.7%) cats was not available.
Radiation therapy was administered to 3 of 118 (2.5%) cats on a
once weekly fractionated basis for 2 to 6 treatments; 2 of 3 (66.7%)
cats were treated with only radiation therapy and 1 cat was treated
with radiation therapy and NSAIDs. One cat received 5 fractions of
6 Gy on a weekly basis, and 1 cat received 6 fractions (dose not
reported); both cats experienced improvement in clinical signs. One
additional cat received 2 fractions of 6 Gy, and radiation therapy sub-
sequently was discontinued because of reported lack of improvement
of clinical signs. One cat was treated using urethral and ureteral stents
in addition to chemotherapy. In 1 additional cat, placement of a ure-
teral stent was unsuccessful.
On multivariable analysis, trigonal disease (OR, 3.91; 95% confidence
interval [CI], 1.40-10.9) and a presenting complaint of lethargy (OR,
3.54; 95% CI, 1.26-9.99) increased the odds of not receiving treatment.
Body weight, age, sex, BUN concentration, serum creatinine concentra-
tion, anorexia, hematuria, vomiting, pollakiuria, stranguria, metastasis at
presentation, and duration of clinical signs were not significantly associ-
ated with receiving treatment.
3.6 | Outcome
Median follow-up time starting from the first visit was 63 days (range,
0-2095 days), and this calculation included 15 untreated cats that were
euthanized at the time of the first visit. Median progression-free survival
time was 113 (95% CI, 69-153) days. Data pertaining to tumor progres-
sion was available for 81 of 118 (68.6%) cats; 45 of 81 (55.6%) cats had
documented progression at a median of 116 days (range, 3-459 days).
Documented progression occurred in 9 of 31 (29.0%) untreated cats,
22 of 28 (78.6%) cats treated without partial cystectomy, and 14 of
22 (63.6%) cats that underwent partial cystectomy, including 4 of
9 (44.4%) cats that reportedly had completely excised tumors based on
histopathology findings. The median time to tumor recurrence in cats
that underwent partial cystectomy was 205 days (range, 42-459 days).
Development or increased size of regional or distant metastatic disease,
or both was documented in 11 of 66 (16.7%) cats with available data at
a median of 176 days (range, 43-407 days). The sites of metastatic
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progression included lungs (4/11; 36.4%), lymph nodes (3/11; 27.3%),
abdominal carcinomatosis (3/11; 27.3%), tissue adjacent to the urinary
bladder ([possible body wall] 2/11; 18.2%), kidney and ureter (1/11;
9.1%), pancreas (1/11; 9.1%), liver (1/11; 9.1%), omentum (1/11; 9.1%),
small intestine (1/11; 9.1%), and sacral vertebra (1/11; 9.1%). Necropsy
was performed on 31 of 118 (26.3%) cats, and metastatic disease was
documented in 6 of 31 (19.4%) cats on necropsy examination. Sites of
metastatic disease on necropsy included kidneys, liver, and abdominal
lymph nodes (1/6; 16.7%); pancreas (1/6; 16.7%); lungs, pancreatic
lymph nodes and mesentery, renal capsule, abdominal lymph nodes,
and lymphatic and vascular obstruction with development of chyloa-
bdomen (1/6; 16.7%); and, carcinomatosis (3/6; 50.0%). Overall, at
study completion, metastatic disease was documented in 25 of
118 (21.2%) cats (including both cats that had metastatic disease at
the time of presentation and those that developed metastatic dis-
ease at a later date). One cat with suspected tumor extension into
the ventral body wall had a prior FNA performed for evaluation of
the bladder tumor (no surgery was performed on this cat). Two cats
that developed abdominal carcinomatosis also previously had FNA
performed for evaluation of the bladder tumor (no surgery was per-
formed on these cats), and 1 cat that developed abdominal carcino-
matosis previously underwent celiotomy without cystectomy.
At the time of analysis, 4 of 118 (3.4%) cats were alive, 77 of
118 (65.3%) cats were dead, and 37 of 118 (31.4%) cats were lost to
follow-up at a median of 30 days post-visit (IQR, 8-180; range,
1-541). Of the deceased cats, 68 of 77 (88.3%) were euthanized, 5 of
77 (6.5%) died of natural causes, and cause of death was not reported
in 4 of 77 (5.2%) cats. Among the 77 cats that died or were eutha-
nized, 56 (72.7%) deaths were attributed to progressive urinary tract
neoplasia with 54 of 56 (96.4%) being euthanized and 2 of 56 (3.6%)
dying. Seven of 77 (9.1%) deaths were attributed to other disease
conditions, whereas the reason for death was unknown in 14 of
77 (18.2%) cats.
Median survival time for all cats was 155 days (95% CI,
110-222 days). The median survival time was 46 days (95% CI,
8-82 days) for untreated cats, 176 days (95% CI, 113-240 days) for cats
treated without partial cystectomy, and 294 days (95% CI, 212-626 days)
for cats treated by partial cystectomy with or without other treatments.
On unadjusted analysis, survival increased significantly (P < .001) when
comparing cats across the ordered treatment groups: no treatment, treat-
ment without partial cystectomy, treatment with partial cystectomy
(Figure 1). Cystectomy (HR, 0.31; 95% CI, 0.17-0.87) and treatment with
NSAIDs (HR, 0.55; 95% CI, 0.33-0.93) were significantly associated with
longer survival times on multivariable analysis. The estimated hazard of
death for cats that had both cystectomy and treatment with NSAIDs was
significantly decreased (HR, 0.17; 95% CI, 0.08-0.38) compared to cats
that had neither treatment. Age, sex, body weight, duration of clinical
signs, serum creatinine concentration, trigonal location, urethral involve-
ment, chemotherapy, radiation therapy, and metastasis at diagnosis were
not significantly associated with overall survival. Estimated 1- and 2-year
survival rates were 6.7% and 2.2% for untreated cats, 0% and 0% for cats
treated without cystectomy, and 28.0% and 8.0% for cats treated with
partial cystectomy with or without other treatments, respectively.
4 | DISCUSSION
To date, information on prognosis and recommended treatments for
cats with TCC of the lower urinary tract has been limited because of a
lack of data. Our results demonstrate the importance of treatment
with cystectomy and NSAIDs in cats with TCC. Our findings highlight
several important differences between dogs and cats with TCC,
including tumor location, treatment modalities with the greatest effect
on outcome, disease progression, and prognosis.
Many of the cats in our study had a history of lower urinary tract
disease, and the majority of cats (92/118; 78.0%) were evaluated by
veterinarians for urinary tract signs or disease before diagnosis. It is
possible that the diagnosis of TCC and subsequent treatment may
have been delayed in many of these cats because of the lack of inclu-
sion of TCC as a differential diagnosis. Alternatively, prior lower
urinary tract disease and inflammation may have predisposed these
cats to the development of TCC. Nevertheless, these findings empha-
size the importance of diagnostic testing to evaluate for potential neo-
plasia of the lower urinary tract even in cats with a history of other
common forms of lower urinary disease, particularly when signs are
recurrent or refractory to treatment.
Location of TCC appears to be more variable in cats than in dogs,
but the trigone appears to be the most common location for occur-
rence in both species. Whereas trigonal disease is reported in the
majority of dogs with TCC, we found trigonal disease in only 32 of
118 (27.1%) cats with TCC.5 Although TCC in both dogs and cats is
typically invasive in nature (similar to high-grade, invasive TCC in
humans), relative to tumor location, TCC in cats may be a better
model for TCC in humans because this neoplasm affects the trigone in
only 23% of human patients with urinary bladder TCC.8,15 Thus, the
treatment limitations associated with trigonal location of TCC in dogs
F IGURE 1 Kaplan-Meier estimates of survival with different
treatment groups. Survival increased significantly (P < .001) when
comparing cats across the ordered treatment groups: no treatment,
treatment without partial cystectomy, treatment with partial
cystectomy
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may not be as applicable in the treatment of this disease in cats and
humans. Importantly, when TCC was located in the trigone of cats in
our study, these cats were less likely to receive treatment. This finding
supports the influence of location of TCC on treatments pursued and
overall outcomes in these cats, because receiving no treatment was
associated with significantly shorter survival.
The potential for seeding TCC within the abdomen or body wall
after FNA or biopsy of the tumor as well as peritoneal surgery has
been well documented in dogs with TCC.3,4,9,16-18 One cat in our
study developed potential extension of TCC into the ventral body wall
after FNA, and 3 of 118 (2.5%) cats developed abdominal carcinoma-
tosis after FNA (2/3; 66.7%) or celiotomy with urinary surgery (1/3;
33.3%). Therefore, as with TCC in dogs, it is important to consider the
potential for neoplastic seeding after tumor sampling (FNA or biopsy)
or laparotomy with urinary tract surgery in cats with lower urinary
tract TCC. However, given the limited number of cats that developed
this complication in our study as well as the relatively poor survival
times for cats with TCC, ultimately obtaining a diagnosis and providing
treatment generally should be pursued, after careful consultation with
owners, in an effort to improve the outcomes of affected cats.
The role of surgery in the treatment of dogs with TCC generally has
been considered limited because of the typical trigonal location, high fre-
quency of urethral involvement, and commonly documented metastatic
disease at the time of diagnosis.5,9 However, a recent study on outcomes
in 37 dogs that underwent partial cystectomy with or without other non-
surgical treatments for TCC found relatively improved outcomes, despite
attaining histopathologically incomplete excision in 60% of the cases.19
Total cystectomy is not currently pursued in many dogs, and the manage-
ment of dogs with lower urinary tract TCC often is palliative in nature
with placement of urethral or ureteral stents to maintain patency of the
urinary tract without directly altering tumor progression.9
In cats with TCC in our study, partial cystectomy was associated
with significantly improved survival times (when compared to cats not
undergoing treatment or cats undergoing treatment not including
cystectomy). Cats that underwent partial cystectomy as part of their
treatment protocol experienced the longest median survival time and
highest 1- and 2-year survival rates. Interestingly, however, although
untreated cats had the shortest median survival time, higher 1- and
2-year survival rates were seen in this subgroup than in cats that were
treated without cystectomy. We hypothesize that this finding may be
attributable to a less aggressive form of disease in a small number of
cats that have the potential for longer survival without treatment.
These cats may have fewer clinical signs associated with TCC and,
subsequently, owners may be less inclined to treat them. However, a
potential incorrect diagnosis of TCC in such cats cannot be ruled out.
A relatively large proportion of cats in our study (28/118; 23.7%)
underwent partial cystectomy; no cats underwent radical cystectomy.
Partial cystectomy was performed in only 2 cats with trigonal disease.
Although the postoperative complication rate was relatively low (6/28;
21.4%), 3 of 6 (50.0%) of the complications were considered major, and
both cats with trigonal tumors that underwent partial cystectomy devel-
oped major complications. Given the potential for major complications
after cystectomy in cats with trigonal disease, the possible role of
surgery in these patients should be further investigated with additional
studies because of the small sample size of cats with trigonal tumors that
underwent partial cystectomy in our study. Importantly, 14 of
22 (63.6%) cats that underwent partial cystectomy developed recurrence
of TCC, and recurrence was seen in a large proportion (4/9; 44.4%) of
cats that reportedly had completely excised TCC. Overall, however, our
data suggests that partial cystectomy can be considered a viable treat-
ment option in cats with TCC, and this surgical procedure can result in
improved outcomes for these patients. Additional studies are required to
determine the role of radical cystectomy on outcomes in cats with TCC.
A single cat in our study underwent urethral and bilateral ureteral
stent placement. However, 14 of 118 (11.9%) cats had evidence of
urethral TCC involvement, 14 of 118 (11.9%) cats had evidence of
ureteral obstruction, and 6 of 118 (5.1%) cats had evidence of both
urethral and ureteral involvement of TCC. This data suggests a possi-
ble role for interventional radiology procedures such as urethral and
ureteral stenting to maintain patency of the urinary tract in an effort
to improve the longevity and quality of life of cats with TCC in the
face of malignant urinary obstruction. Several studies have evaluated
the use of urethral stents in cats with malignant urethral obstruction
and have found favorable outcomes after these minimally invasive
procedures.20-22 Although reports regarding the use of ureteral stents
and SC ureteral bypass devices in cats with malignant causes of ure-
teral obstruction are lacking, these devices commonly are used in cats
with other causes of ureteral obstruction and in dogs with malignant
ureteral obstruction. Possible use of these devices in cats with ure-
teral obstruction secondary to TCC should be considered in an effort
to provide palliation for obstructive local disease.23,24
Radiation therapy has been utilized infrequently in the treatment of
TCC in dogs, and this appears to be similar in cats as evidenced by only
3 of 118 (2.5%) cats in our study undergoing radiation therapy.11,12
The radiation therapy protocols used in the cats of our study all were
hypofractionated and palliative in intent. Additional studies are needed
to further determine the role of radiation therapy and optimal protocols
for its use in the treatment of both dogs and cats with lower urinary
tract TCC.
In dogs, systemic medical treatments including chemotherapy agents
and COX inhibitors are considered to be mainstay treatments for
TCC.3,8,9 Multimodal medical therapy has been shown to improve
response rates and survival times in dogs with TCC.10,25,26 In our study,
treatment with NSAIDs was associated with prolonged survival for cats
with TCC. Several studies have evaluated the safety of long-term daily
meloxicam and piroxicam in cats, and consensus guidelines have been
published regarding judicious chronic use of NSAIDs in cats.27-31 Adverse
events were reported in a relatively small percentage of cats in our study
treated with NSAIDs (13/49; 26.5%), and, of those adverse events, many
were not definitively correlated with NSAID administration. This data sug-
gests that NSAIDs carry a relatively low risk of complications when used
appropriately and should be considered as part of the treatment strategy
whenever possible for cats with TCC. However, given the retrospective
nature of our study, the frequency or severity of adverse events may
have been underreported, and thorough discussion of possible adverse
events with clients is indicated before long-term use of NSAIDs in cats.
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Although chemotherapy and other treatment modalities ultimately
may play a role in treatment of cats with TCC, our findings suggest
that surgical excision and NSAID administration should be the primary
recommended treatments in cats with lower urinary tract TCC in an
effort to improve outcomes. However, these treatments will not be
possible or appropriate in all cats with lower urinary tract TCC, and
any treatment (relative to no treatment) may result in an improved
outcome for affected cats.
Overall, the prognosis for cats with lower urinary tract TCC is
guarded.14,32 This finding points to a need for improvement in our
management of these patients. Whereas the overall frequency of met-
astatic disease in cats with TCC was at least 25 of 118 (21.2%), the
frequency of documented tumor progression was 45 of 81 (55.6%),
with frequency of recurrence after cystectomy was 14 of 22 (63.6%).
The relatively higher rate of tumor progression emphasizes the need
to improve local control of this disease. Additional studies regarding
radical cystectomy and radiation therapy in cats with TCC are needed
to further determine the role of these treatments on local disease
control and overall outcomes in cats with TCC.
Our study had several limitations. First, the study was retrospec-
tive with resultant potential for incomplete clinical information for
some patients. Many cases were lost to follow-up, which can lead to
underinterpretation or overinterpretation of many findings, including
documentation of metastasis and response to treatment. Because of
wide variability in patient, disease, treatment, and outcome informa-
tion, valid comparisons of outcomes across subgroups of cats could
not be made. For example, it was not possible to make assessments of
the subgroup of cats with trigonal disease that underwent treatment
or cats that underwent treatment with NSAIDs and partial cystectomy
compared to NSAIDs alone and partial cystectomy alone because of
small numbers of cats in these subgroups and multiple potential con-
founders. A second limitation is probable selection bias because aca-
demic institutions primarily contributed cases, and both patient and
client factors likely influenced the type of treatment, if any, that was
administered to individual cats. Additionally, prior care at referring
practices was not accounted for in this data set, which could have
resulted in underestimation of treatment effects or survival times.
Cats may have undergone treatment at a referring veterinary clinic
that may have improved clinical signs or outcome, but no evidence of
any cat undergoing NSAID administration, chemotherapy, or surgery
before referral was noted. Many cats with suspected TCC were
excluded because of lack of cytological or histopathological confirma-
tion, such that the sample size likely did not include all cats with the
disease. Finally, given the long inclusion period of the study, bias may
have originated from changes in the recommended diagnostic and
treatment modalities for these patients over time.
In conclusion, our study represents the largest report to date on
cats with TCC of the lower urinary tract. This information can be
used to inform clinicians and owners about this disease process in
cats and to guide treatment recommendations and discussions on
prognosis. Although the statistically significant findings in this
study emphasize the importance of partial cystectomy and NSAID
administration in cats with TCC, additional work is necessary to
evaluate larger numbers of cats undergoing these and other
treatments.
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